Arteriovenous Malformations: Syndrome Identification and Vascular Management

  • Allan M. ConwayEmail author
  • Robert J. Rosen
Vascular Disease (M Weinberg, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Vascular Disease


Purpose of review

Vascular malformations represent a poorly understood set of conditions that create considerable diagnostic and therapeutic confusion. Historically, extensive surgical resections yielded poor results. More recently, the treatment paradigm has shifted to endovascular therapy such that embolization and sclerotherapy are now considered the first line of treatment. Although there is still a role for traditional surgical techniques, it is now most commonly integrated with endovascular therapies in a hybrid fashion. The goal of this review is to provide a greater understanding of the diagnosis and treatment of vascular malformations.

Recent findings

Vascular malformations can be high-flow (arteriovenous shunting) or low-flow (venous or lymphatic). Clinical presentation and treatment is different for each. Treatment of high-flow lesions must be directed at reducing or eliminating the nidus, usually via super-selective catheterization and embolization. Low-flow lesions are usually treated by direct injection of sclerosing agents under fluoroscopic or ultrasound guidance.


The cornerstone of managing patients with vascular malformations is making the proper diagnosis, which is often challenging. Even after a diagnosis is made, therapy itself may be challenging and generate frustration among patients and providers. Frequently, the treatment of vascular malformations is characterized by only slow and incremental improvements without complete lesion eradication. By combining a thorough understanding of the vascular malformation disease process with an array of endovascular techniques, vascular interventionalists may contribute greatly to the care of these patients.


Vascular disease Arteriovenous malformations Vascular management Arteriovenous shunting Venous or lymphatic 


Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Persaud TVN. Problems of birth defects. From Hippocrates to Thalidomide and after. Persaud TVN Part I Belief, mythology, magic and superstition. Commentary. Baltimore: University Park Press Maryland Publishers; 1977. p. 3–4.Google Scholar
  2. 2.
    • Belov S. Classification, terminology, and nosology of congenital vascular defects. In: Belov S, Loose DA, Weber J, editors. Vascular malformations. Reinbek: Einhorn-Presse; 1989. p. 25–30.Describing a new classification system for vascular anomalies has emerged that is based on advances in the study of these conditions and is useful in contemporary managementGoogle Scholar
  3. 3.
    •• International Society for the Study of Vascular Anomalies. Approved at the 20th ISSVA Workshop, Melbourne, April 2014. Retrieved from current classification system of vascular anomalies as described by the ISSVA.
  4. 4.
    Paltiel HJ, Burrows PE, Kozakewich HP, Zurakowski D, Mulliken JB. Soft-tissue vascular anomalies: utility of US for diagnosis. Radiology. 2000;214(3):747–54.CrossRefPubMedGoogle Scholar
  5. 5.
    Greenspan A, et al. Imaging strategies in the evaluation of soft tissue hemangiomas of the extremities: correlation of the findings of plain radiography, CT, MRI and ultrasonography in 12 histologically proven cases. Skeletal Radiol. 1992;21:8–11.CrossRefGoogle Scholar
  6. 6.
    Jeon YH, Do YS, Shin SW, et al. Ethanol embolization of arteriovenous malformations: results and complications of 33 cases. J Korean Radiol Soc. 2003;49:263–70.CrossRefGoogle Scholar
  7. 7.
    Madani H, Farrant J, Chhaya N, Anwar I, Marmery H, Platts A, et al. Peripheral limb vascular malformations: an update of appropriate imaging and treatment options of a challenging condition. Br J Radiol. 2015;88(1047):20140406.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Blei F, Chianese J. Corticosteroid toxicity in infants treated for endangering hemangiomas: experience and guidelines for monitoring. Intl pediatrics. 1999;14:146–53.Google Scholar
  9. 9.
    •• Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358(24):2649–51.Early description of the use of propranolol to inhibit the growth of infantile hemangiomas.CrossRefPubMedGoogle Scholar
  10. 10.
    Natali J, Merland JJ. Superselective arteriography and therapeutic embolization for vascular malformations (angiodysplasias). J Cardiovasc Surg. 1976;17:465.Google Scholar
  11. 11.
    Osuga K, Hori S, Kitayoshi H, et al. Embolization of high flow arteriovenous malformations: experience with use of superabsorbent polymer microspheres. J Vasc Interv Radiol. 2002;13(11):1125–33.CrossRefPubMedGoogle Scholar
  12. 12.
    Sasaki GH, Pang CY, Wittliff JL. Pathogenesis and treatment of infant skin strawberry hemangiomas: clinical and in vitro studies of hormonal effects. Plast Reconstr Surg. 1984;73(3):359–70.CrossRefPubMedGoogle Scholar
  13. 13.
    •• Yakes WF, Haas DK, Parker SH, et al. Symptomatic vascular malformations: ethanol embolotherapy. Radiology. 1989;170:1059–66.Absolute ethanol was used to perform nine transcatheter embolizations and 21 direct percutaneous puncture embolizations in eight patients with unresectable vascular malformations. The authors showed how ethanol embolotherapy, performed according to strict techniques, can be efficacious in the management of vascular malformations.CrossRefPubMedGoogle Scholar
  14. 14.
    Kerber C. Intracranial cyoanacrylate: a new catheter therapy for arteriovenous malformation. Invest Radiol. 1975;10:536–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Vintner V, Galil KA, Lundie MJ, Kaufmann JCE. The histotoxicity of cyanoacrylates. Neuroradiology. 1985;27:279–91.CrossRefGoogle Scholar
  16. 16.
    Numan F, Omeroglu A, Kara B, Cantaşdemir M, Adaletli I, Kantarci F. Embolization of peripheral vascular malformations with ethylene vinyl alcohol copolymer (Onyx). J Vasc Interv Radiol. 2004;15(9):939–46.CrossRefPubMedGoogle Scholar
  17. 17.
    • Conway AM, Qato K, Drury J, Rosen RJ. Embolization techniques for high-flow arteriovenous malformations with a dominant outflow vein. J Vasc Surg Venous Lymphat Disord. 2015;3(2):178–83.The aim of this study was to assess the management and outcomes of arteriovenous malformations (AVMs) with a dominant outflow vein (DOV) treated with retrograde venous embolization. The authors showed how AVMs with a DOV can be successfully treated by a transvenous approach.CrossRefPubMedGoogle Scholar
  18. 18.
    Cho SK, Do YS, Kim DI, Kim YW, Shin SW, Park KB, et al. Peripheral arteriovenous malformations with a dominant outflow vein: results of ethanol embolization. Korean J Radiol. 2008;9:258–67.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Boxt LM, Levin DC, Fellows KE. Direct puncture angiography in congenital venous malformations. AJR. 1983;140:135.CrossRefPubMedGoogle Scholar
  20. 20.
    Mitchell S, Shah A, Schwengel D. Pulmonary artery pressure changes during ethanol embolization procedures to treat vascular malformations: can cardiovascular collapse be predicted? JVIR. 2006;17:253–62.CrossRefPubMedGoogle Scholar
  21. 21.
    Hsu TS, Weiss RA. Foam sclerotherapy: a new era. Arch Dermatol. 2003;139(11):1494–6.CrossRefPubMedGoogle Scholar
  22. 22.
    • Yang Y, Sun M, Ma Q, Cheng X, Ao J, Tian L, et al. Bleomycin A5 sclerotherapy for cervicofacial lymphatic malformations. J Vasc Surgery. 2011;53:150–5.The purpose of this study was to document the results of bleomycin A5 sclerotherapy for cervicofacial lymphatic malformations (LM). These data suggest bleomycin A5 is a safe and effective intralesional agent for the treatment of macrocystic LMs, superficial oral mucosa LM, and localized deep microcystic lesions.CrossRefGoogle Scholar
  23. 23.
    Muir T, Kirsten M, Fourie P, Dippenaar N, Ionescu GO. Intralesional bleomycin injection (IBI) treatment for haemangiomas and congenital vascular malformations. Pediatr Surg Int. 2004;19:766–73.CrossRefPubMedGoogle Scholar
  24. 24.
    Khmamouche MR, Debbagh A, Mahfoud T, Aassab R, Lkhoyaali S, Ichou M, et al. Flagellate erythema secondary to bleomycin: a new case report and review of the literature. J Drugs Dermatol. 2014;13(8):983–4.PubMedGoogle Scholar
  25. 25.
    Klippel M, Trenaunay P. Du naevus variqueux osterhypertrophique. Arch Gen Med (Paris). 1900;3:611.Google Scholar
  26. 26.
    Parkes Weber F. Haemangiectatic hypertrophy of the limbs: congenital phlebarterietasis and so-called congenital varicose veins. Br J Child Dis. 1918;15:13.Google Scholar
  27. 27.
    Huang Y, Jiang M, Li W. Endovenous laser treatment combined with a surgical strategy for treatment of venous insufficiency in lower extremity: report of 208 cases. J Vasc Surg. 2005;42(3):494–501.CrossRefPubMedGoogle Scholar
  28. 28.
    • Howlett DC, Roebuck DJ, Frazer CK, Ayers B. The use of ultrasound in the venous assessment of lower limb Klippel-Trenaunay syndrome. Eur J Radiol. 1994;18:224–6.Colour Doppler ultrasound was used to study the affected lower limbs of a group of patients with the Klippel-Trenaunay syndrome. From this study, the deep venous aplasia said to occur in the condition would appear to be less common than previously thought.CrossRefPubMedGoogle Scholar
  29. 29.
    Greinwald JH Jr, Burke DK, Sato Y, Poust RI, Kimura K, Bauman NM, et al. Treatment of lymphangiomas in children: an update of picibanil (OK-432) sclerotherapy. Otolaryngol Head Neck Surg. 1999;121(4):381–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Kinmonth JB, Young AE, Edwards JM, O'Donnell TF, Thomas ML. Mixed vascular deformities of the lower limbs, with particular reference to lymphography and surgical treatment. Br J Surg. 1976;63(12):899–906.CrossRefPubMedGoogle Scholar
  31. 31.
    Mendel T, Louis DS. Major vascular malformations of the upper extremity: long-term observation. J Hand Surg. 1997;22A:302.CrossRefGoogle Scholar
  32. 32.
    Cronenwett JL, Johnston KW. Rutherford’s vascular surgery. 7th ed. Philadelphia: Saunders Elsevier; 2010. p. 1072–5.Google Scholar
  33. 33.
    Pireau N, Boon LM, Poilvache P, Docquier PL. Surgical treatment of intra-articular knee venous malformations: when and how? J Pediatr Orthop. 2016;36(3):316–22.CrossRefPubMedGoogle Scholar
  34. 34.
    Johnson JN, Shaughnessy WJ, Stans AA. Management of knee arthropathy in patients with vascular malformations. J Pediatr Orthop. 2009;29(4):380–4.CrossRefPubMedGoogle Scholar
  35. 35.
    Cil BE, Vargel I, Geyik S, Peynircioglu B, Cavusoglu T. Venous vascular malformations of the craniofacial region: pre-operative embolisation with direct percutaneous puncture and N-butyl cyanoacrylate. Br J Radiol. 2008;81(972):935–9.CrossRefPubMedGoogle Scholar
  36. 36.
    James CA, Braswell LE, Wright LB. Preoperative sclerotherapy of facial venous malformations: impact on surgical parameters and long-term follow-up. J Vasc Intervent Radiol. 2011;22(7):953–60.CrossRefGoogle Scholar
  37. 37.
    Uller W, El-Sobky S, Alomari AI, Fishman SJ, Spencer SA, Taghinia AH, et al. Preoperative embolization of venous malformations using n-butyl cyanoacrylate. Vasc Endovascular Surg. 2018;
  38. 38.
    Eivazi B, Werner JA. Extracranial vascular malformations (hemangiomas and vascular malformations) in children and adolescents—diagnosis, clinic, and therapy. GMS Curr Top Otorhinolaryngol Head Neck Surg. 2014;13

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.The AVM Center at Lenox HillLenox Hill Heart & Vascular InstituteNew YorkUSA
  2. 2.Lenox Hill HospitalNew YorkUSA

Personalised recommendations